860502P

C2 Ceramide (d18:1/2:0)

Avanti Research^™ - A Croda Brand 860502P, powder

• 別名: N-acetoyl-D-erythro-sphingosine
• 実験式（ヒル表記法）: C₂₀H₃₉NO₃
• CAS番号: 195194-58-2
• 分子量: 341.53
• MDL番号: MFCD07374281
• UNSPSCコード: 12352211
• NACRES: NA.25

特性

• フォーム: powder
• 包装: pkg of 1 × 5 mg (860502P-5mg)
• メーカー／製品名: Avanti Research^™ - A Croda Brand 860502P
• 脂質タイプ: sphingolipids
• 輸送温度: dry ice
• 保管温度: −20°C
• SMILES記法: OC[C@]([H])(NC(C)=O)[C@]([H])(O)/C=C/CCCCCCCCCCCCC
• InChI: 1S/C20H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20(24)19(17-22)21-18(2)23/h15-16,19-20,22,24H,3-14,17H2,1-2H3,(H,21,23)/b16-15+/t19-,20+/m0/s1
• InChI Key: BLTCBVOJNNKFKC-QUDYQQOWSA-N

詳細

詳細

C2 Ceramide (d18:1/2:0) is a short-chain ceramide. In general ceramides are synthesized by de novo pathway from palmitic acid via series of intermediates to ceramidein the presence of dihydroceramide Δ4-desaturase.[1]

アプリケーション

C2 Ceramide (d18:1/2:0) has been used to treat protoplasts for reactive oxygen species generation[2] and as an substrate for sphingomyelin synthase 2 enzyme.[3] It is suitable for use as an exogenous supplement in hippocampal cell cultures for the production of 2-hydroxyeicosatetraenoic acid (12-(S)-HETE).[4]

生物化学的／生理学的作用

C2 ceramide inhibits the progression of human bronchocarcinoma by modulating the matrix metallopeptidases-2 levels. It also inhibits glioma invasion[5] and induces apoptosis in HT-29 and HCT-116 human colon cancer cells.[6] Treatment of myotubes with C2-ceramide leads to decrease in glucose uptake and glycogen synthesis.[1] C2 along with C6 ceramides induces insulin resistance in myoblastic C2C12 cell line and L6 myotubes.[7]

包装

5 mL Amber Glass Screw Cap Vial (860502P-5mg)

法的情報

Avanti Research is a trademark of Avanti Polar Lipids, LLC

安全性情報

• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3